基本信息
季红斌 男 博导 中国科学院分子细胞科学卓越创新中心
email: hbji@sibcb.ac.cn
address: 上海市岳阳路320号
postalCode:
email: hbji@sibcb.ac.cn
address: 上海市岳阳路320号
postalCode:
招生信息
招生专业
071009-细胞生物学
招生方向
肺癌发病的分子机理
教育背景
1995-09--2000-07 中科院上海生命科学院 博士学位
工作经历
工作简历
2007-05~现在, 中国科学院上海生命科学研究院生物化学与细胞生物学研究所, 研究员2000-08~2007-04,美国哈佛大学医学院, 博士后、讲师1995-09~2000-07,中科院上海生命科学院, 博士学位
教授课程
肿瘤生物学细胞生物学Cancer Cell
专利与奖励
奖励信息
(1) 第七届上海青年科技英才, 省级, 2014(2) 肺腺癌的分子分型及临床应用, 二等奖, 省级, 2013
专利成果
( 1 ) LSD1基因的用途及相关产品, 2023, 第 1 作者, 专利号: CN116694758A( 2 ) 癌症靶标及其应用, 2022, 第 1 作者, 专利号: CN114949217A( 3 ) 联合治疗肺粘液性腺癌的药物, 2022, 第 1 作者, 专利号: CN114632084A( 4 ) 诊断和治疗化疗耐药小细胞肺癌的新靶点及其应用, 2022, 第 1 作者, 专利号: CN114438159A( 5 ) 诊断和治疗化疗耐药小细胞肺癌的新靶点及其应用, 2022, 第 1 作者, 专利号: CN114438159A( 6 ) 利用肠道细菌检测早期肺癌, 2021, 第 2 作者, 专利号: CN113151512A( 7 ) 治疗ARID2或HSPA1A介导的疾病的方法和组合物, 2020, 第 1 作者, 专利号: CN112107684A
出版信息
发表论文
(1) Cullin5 deficiency promotes small-cell lung cancer metastasis by stabilizing integrin �� 1, THE JOURNAL OF CLINICAL INVESTIGATION, null, 第 23 作者(2) Comments on 'Adeno-to-squamous transition drives resistance to KRAS inhibition in LKB1 mutant lung cancer'., J Mol Cell Biol., 2024, (3) EML4-ALK fusions drive lung adeno-to-squamous transition through JAK-STAT activation., J Exp Med., 2024, (4) Proteogenomic characterization of small cell lung cancer identifies biological insights and subtype-specific therapeutic strategies., Cell., 2024, 第 12 作者(5) Cryoablation triggers type I interferon-dependent antitumor immunity and potentiates immunotherapy efficacy in lung cancer., J Immunother Cancer., 2024, 第 12 作者(6) Adeno-to-squamous transition drives resistance to KRAS inhibition in LKB1 mutant lung cancer., Cancer Cell., 2024, (7) Counteracting lineage-specific transcription factor network finely tunes lung adeno-to-squamous transdifferentiation through remodeling tumor immune microenvironment., Natl Sci Rev, 2023, 第 23 作者 通讯作者(8) Oxidative stress-triggered Wnt signaling perturbation characterizes the tipping point of lung adeno-to-squamous transdifferentiation, SIGNAL TRANSDUCTION AND TARGETED THERAPY, 2023, 第 17 作者(9) KMT2D deficiency drives lung squamous cell carcinoma and hypersensitivity to RTK-RAS inhibition, CANCER CELL, 2023, 第 31 作者(10) Therapeutic targeting of the mevalonate-geranylgeranyl diphosphate pathway with statins overcomes chemotherapy resistance in small cell lung cancer, NATURE CANCER, 2022, 第 19 作者 通讯作者(11) Identification of TAZ as the essential molecular switch in orchestrating SCLC phenotypic transition and metastasis, Identification of TAZ as the essential molecular switch in orchestrating SCLC phenotypic transition and metastasis, 国家科学评论:英文版, 2022, 第 26 作者(12) Identification of TAZ as the essential molecular switch in orchestrating SCLC phenotypic transition and metastasis, NATIONAL SCIENCE REVIEW, 2022, 第 26 作者(13) Loss of TET reprograms Wnt signaling through impaired demethylation to promote lung cancer development, PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2022, 第 8 作者 通讯作者(14) A mesenchymal-like subpopulation in non-neuroendocrine SCLC contributes to metastasis, A mesenchymal-like subpopulation in non-neuroendocrine SCLC contributes to metastasis, JOURNAL OF GENETICS AND GENOMICS, 2021, 第 7 作者 通讯作者(15) Nanog maintains stemness of Lkb1-deficient lung adenocarcinoma and prevents gastric differentiation (vol 13, e12627, 2021), EMBO MOLECULAR MEDICINE, 2021, 第 13 作者(16) 腺鳞癌转化在肺癌耐药中的功能和机制研究, Functional and mechanistic studies on the transition from adenocarcinoma to squamous cell carcinoma in lung cancer drug resistance, 生物医学转化, 2021, 第 4 作者(17) Targeting HSPA1A in ARID2-deficient lung adenocarcinoma, Targeting HSPA1A in ARID2-deficient lung adenocarcinoma, NATIONAL SCIENCE REVIEW, 2021, 第 22 作者 通讯作者(18) A systematic dissection of the epigenomic heterogeneity of lung adenocarcinoma reveals two different subclasses with distinct prognosis and core regulatory networks, GENOME BIOLOGY, 2021, 第 17 作者 通讯作者(19) Chromobox 4 facilitates tumorigenesis of lung adenocarcinoma through the Wnt/��-catenin pathway, NEOPLASIA, 2021, 第 16 作者 通讯作者(20) Integrative analysis of multi-omics data reveals the heterogeneity and signatures of immune therapy for small cell lung cancer, CLINICAL AND TRANSLATIONAL MEDICINE, 2021, 第 16 作者 通讯作者(21) Lung stem cells in regeneration and tumorigenesis, Lung stem cells in regeneration and tumorigenesis, JOURNAL OF GENETICS AND GENOMICS, 2021, 第 4 作者 通讯作者(22) Phase separation of EML4-ALK in firing downstream signaling and promoting lung tumorigenesis, CELL DISCOVERY, 2021, 第 9 作者 通讯作者(23) Stem Cell Factor SOX2 Confers Ferroptosis Resistance in Lung Cancer via Upregulation of SLC7A11, CANCER RESEARCH, 2021, 第 15 作者 通讯作者(24) PI3K/Akt/mTOR signaling orchestrates the phenotypic transition and chemo-resistance of small cell lung cancer, PI3K/Akt/mTOR signaling orchestrates the phenotypic transition and chemo-resistance of small cell lung cancer, JOURNAL OF GENETICS AND GENOMICS, 2021, 第 11 作者 通讯作者(25) In vivo miRNA knockout screening identifies miR-190b as a novel tumor suppressor, PLOS GENETICS, 2020, 第 9 作者 通讯作者(26) 肺癌耐药的新机制——肺癌的病理转化, 癌症, 2020, 第 6 作者(27) Specific gut microbiome signature predicts the early-stage lung cancer, GUT MICROBES, 2020, 第 18 作者 通讯作者(28) Keratin 14-high subpopulation mediates lung cancer metastasis potentially through Gkn1 upregulation, ONCOGENE, 2019, 第 10 作者 通讯作者(29) Lung cancer deficient in the tumor suppressor GATA4 is sensitive to TGFBR1 inhibition, NATURE COMMUNICATIONS, 2019, 第 21 作者 通讯作者(30) Pathological transition as the arising mechanism for drug resistance in lung cancer, Pathological transition as the arising mechanism for drug resistance in lung cancer, CANCER COMMUNICATIONS, 2019, 第 4 作者 通讯作者(31) Lung regeneration by multipotent stem cells residing at the bronchioalveolar-duct junction (vol 51, pg 728, 2019), NATURE GENETICS, 2019, 第 26 作者(32) Branched-Chain Amino Acid Metabolic Reprogramming Orchestrates Drug Resistance to EGFR Tyrosine Kinase Inhibitors, CELL REPORTS, 2019, 第 27 作者 通讯作者(33) Kdm1a promotes SCLC progression by transcriptionally silencing the tumor suppressor Rest, BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2019, 第 6 作者 通讯作者(34) HER2 exon 20 insertions in non-small-cell lung cancer are sensitive to the irreversible pan-HER receptor tyrosine kinase inhibitor pyrotinib, ANNALS OF ONCOLOGY, 2019, (35) Smart and dual-targeted BSA nanomedicine with controllable release by high autolysosome levels, COLLOIDS AND SURFACES B-BIOINTERFACES, 2019, 第 8 作者(36) Landscape of transcriptional deregulation in lung cancer, BMC GENOMICS, 2018, 第 3 作者 通讯作者(37) In vivo CRISPR screening unveils histone demethylase UTX as an important epigenetic regulator in lung tumorigenesis, PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2018, 第 26 作者 通讯作者(38) Evolution from genetics to phenotype: reinterpretation of NSCLC plasticity, heterogeneity, and drug resistance, Evolution from genetics to phenotype: reinterpretation of NSCLC plasticity, heterogeneity, and drug resistance, PROTEIN & CELL, 2017, 第 3 作者(39) Cell Division Cycle 42 plays a Cell type-Specific role in Lung Tumorigenesis, SCIENTIFIC REPORTS, 2017, 第 14 作者(40) YAP Suppresses Lung Squamous Cell Carcinoma Progression via Deregulation of the DNp63-GPX2 Axis and ROS Accumulation, CANCER RESEARCH, 2017, 第 17 作者 通讯作者(41) Evidence, Mechanism, and Clinical Relevance of the Transdifferentiation from Lung Adenocarcinoma to Squamous Cell Carcinoma, THE AMERICAN JOURNAL OF PATHOLOGY, 2017, 第 7 作者(42) A novel BMX variant promotes tumor cell growth and migration in lung adenocarcinoma, ONCOTARGET, 2017, 第 10 作者 通讯作者(43) Identification of TRA2B-DNAH5 fusion as a novel oncogenic driver in human lung squamous cell carcinoma, CELL RESEARCH, 2016, 第 22 作者 通讯作者(44) Cetuximab-modified mesoporous silica nano-medicine specifically targets EGFR-mutant lung cancer and overcomes drug resistance, SCIENTIFIC REPORTS, 2016, 第 5 作者 通讯作者(45) Squamous Transition of Lung Adenocarcinoma and Drug Resistance, TRENDS IN CANCER, 2016, 第 3 作者 通讯作者(46) LKB1 Inactivation Elicits a Redox Imbalance to Modulate Non-small Cell Lung Cancer Plasticity and Therapeutic Response, CANCER CELL, 2015, 第 19 作者(47) YAP Promotes Malignant Progression of Lkb1-Deficient Lung Adenocarcinoma through Downstream Regulation of Survivin, CANCER RESEARCH, 2015, 第 12 作者 通讯作者(48) YAP inhibits squamous transdifferentiation of Lkb1-de���cient lung adenocarcinoma through ZEB2-dependent DNp63 repression, Nat Commun, 2014, 第 1 作者 通讯作者(49) Transdifferentiation of lung adenocarcinoma in mice with Lkb1 deficiency to squamous cell carcinoma, NATURE COMMUNICATIONS, 2014, 第 11 作者(50) Two co-existing germline mutations P53 V157D and PMS2 R20Q promote tumorigenesis in a familial cancer syndrome, CANCER LETTERS, 2014, 第 12 作者(51) VGLL4 functions as a new tumor suppressor in lung cancer by negatively regulating the YAP-TEAD transcriptional complex., CELL RESEARCH, 2014, 第 15 作者 通讯作者(52) Synthesis and evaluation of 2-anilinopyrimidines bearing 3-aminopropamides as potential epidermal growth factor receptor inhibitors, EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2014, 第 3 作者(53) NEDD9 promotes lung cancer metastasis through epithelial- mesenchymal transition, INTERNATIONAL JOURNAL OF CANCER, 2014, 第 14 作者 通讯作者(54) Regulation of EGFR nanocluster formation by ionic protein-lipid interaction, CELL RESEARCH, 2014, 第 12 作者(55) A Peptide Mimicking VGLL4 Function Acts as a YAP Antagonist Therapy against Gastric Cancer, CANCER CELL, 2014, 第 15 作者 通讯作者(56) Integrative Genomic Analysis Reveals a High Frequency of LKB1 Genetic Alteration in Chinese Lung Adenocarcinomas, JOURNAL OF THORACIC ONCOLOGY, 2014, 第 11 作者 通讯作者(57) ANCCA Protein Expression is a Novel Independent Poor Prognostic Marker in Surgically Resected Lung Adenocarcinoma, ANNALS OF SURGICAL ONCOLOGY, 2013, 第 13 作者(58) Nitric oxide donating anilinopyrimidines: Synthesis and biological evaluation as EGFR inhibitors, EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2013, 第 8 作者(59) Novel Hybrids of (Phenylsulfonyl)furoxan and Anilinopyrimidine as Potent and Selective Epidermal Growth Factor Receptor Inhibitors for Intervention of Non-Small-Cell Lung Cancer, JOURNAL OF MEDICINAL CHEMISTRY, 2013, 第 8 作者
科研活动
科研项目
( 1 ) 体细胞与物种间进化与退化的综合演化研究及理论模型的建立, 参与, 国家任务, 2023-01--2027-12( 2 ) 干细胞成瘤的时空演化规律及干预策略, 负责人, 国家任务, 2022-12--2027-11( 3 ) 小细胞肺癌化疗耐药的分子细胞基础及克服策略, 负责人, 国家任务, 2021-01--2025-12( 4 ) 内源生物活性小分子在组织稳态调控及肿瘤发生发展中的作用及机制研究, 参与, 国家任务, 2020-12--2025-11( 5 ) 癌细胞在肺腺鳞癌转分化过程中的变异与适应性规律研究, 负责人, 国家任务, 2018-01--2019-12( 6 ) 肺组织生理病理动态转化的小鼠模型和类器官模型的构建及研究, 负责人, 国家任务, 2017-01--2021-12( 7 ) 肿瘤恶性进展及耐药复发中的可塑性变化及机理, 负责人, 中国科学院计划, 2016-07--2021-06( 8 ) 肺腺鳞癌转分化的分子机制研究, 负责人, 地方任务, 2015-05--2018-04( 9 ) 肿瘤细胞与胞外基质的相互作用调控肺腺癌向鳞癌转分化的作用及其分子机制, 负责人, 国家任务, 2015-01--2019-12( 10 ) 呼吸系统肿瘤, 负责人, 国家任务, 2014-01--2017-12( 11 ) EGFR质膜动态定位的功能和机制研究, 负责人, 国家任务, 2014-01--2017-12( 12 ) 炎症相关肿瘤中癌基因和抑癌基因的异常调控网络研究, 负责人, 国家任务, 2012-01--2016-08
参与会议
(1)恶性肿瘤的细胞异质性、可塑性与精准医学 2015-10-11(2)LKB1调控肺癌转移及腺鳞癌转分化 2015-09-24(3)Evidence and mechanism for transdifferentiation of lung adenocarcinoma to squamous cell carcinoma 2015-06-05(4)Transdifferentiation of lung adenocarcinoma to squamous cell carcinoma 2014-10-25(5)Transdifferentiation of lung adenocarcinoma to squamous cell carcinoma 2014-06-26(6)Molecular mechanisms in lung tumorigenesis 2014-05-27(7)LKB1 in lung adenocarcinoma to squamous cell carcinoma transdifferentiation 中国细胞生物学学会2013年全国学术大会 2013-04-19